Biochemistry

Role of Caspase-1 in the Pathogenesis of Inflammatory-Associated Chron | JIR – Dove Medical Press

Meseret Derbew Molla,1 Yonas Akalu,2 Zeleke Geto,3 Baye Dagnew,2 Birhanu Ayelign,4 Tewodros Shibabaw1

1Department of Biochemistry, School of Medicine, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia; 2Department of Human Physiology, School of Medicine, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia; 3Department of Biomedical Sciences, School of Medicine, College of Medicine and Health Sciences, Wollo University, Dessie, Ethiopia; 4Department of Immunology and Molecular Biology, School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia

Correspondence: Meseret Derbew MollaDepartment of Biochemistry, School of Medicine, College of Medicine and Health Sciences, University of Gondar, PO Box 196, Gondar, Ethiopia, Tel +251918331617Email messidrm19@gmail.com

Abstract: Caspase-1 is the first and extensively studied inflammatory caspase that is activated through inflammasome assembly. Inflammasome is a cytosolic formation of multiprotein complex that aimed to start inflammatory response against infections or cellular damages. The process leads to an auto-activation of caspase-1 and consequent maturation of caspase-1 target molecules such as interleukin (IL)-1 and IL-18. Recently, the role of caspase-1 and inflammasome in inflammatory-induced noncommunicable diseases (NCDs) like obesity, diabetes mellitus (DM), cardiovascular diseases (CVDs), cancers and chronic respiratory diseases have widely studied. However, their reports are distinct and even they have reported contrasting role of caspase-1 in the development and progression of NCDs. A few studies have reported that caspase-1/inflammasome assembley has a protective role in the initiation and progression of these diseases through the activation of the noncanonical caspase-1 target substrates like gasdermin-D and regulation of immune cells. Conversely, others have revealed that caspase-1 has a direct/indirect effect in the development and progression of several NCDs. Therefore, in this review, we systematically summarized the role of caspase-1 in the development and progression of NCDs, especially in obesity, DM, CVDs and cancers.

Keywords: caspase-1, inflammasome, IL-1, IL-18, noncommunicable diseases

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

See the original post here:
Role of Caspase-1 in the Pathogenesis of Inflammatory-Associated Chron | JIR - Dove Medical Press

Biochemistry

Global Chlorfenapyr Market Executive Summary and Analysis by Top Players 2020-2024: BASF, American Cyanamid, Dow AgroScience, Triveni Interchem,…

This report assists with understanding the general market and to perceive the development opportunities in the global Chlorfenapyr Market. The report moreover includes thoroughly detailed information about the significant market players dominating in the Chlorfenapyr Market.

The organizations shrouded in the report can be assessed based on their most recent activities, monetary and business plans illustration, key patterns, and product portfolio offered in the Chlorfenapyr industry, key business methodologies by the organizations in order to remain competitive in the market.

The global Chlorfenapyr Industry Study shows in detail the working of key market players (BASF, American Cyanamid, Dow AgroScience, Triveni Interchem, Kenvos, Nanjing Gaozheng Agrochemical, Kaifeng Bokai Biochemistry, Yonglong Chemical, Hunan Dejia Biochemical Tech, Eastman Chemical), Types (Type 1, Type 2, ), Applications (Application 1, Application 2, ) producers, and wholesalers. The investigation additionally traces the limitations and elements impacting the global interest for Global Market.

Get Sample [emailprotected] https://www.regalintelligence.com/request-sample/87892

The Chlorfenapyr-market research report examines various basic requirements, for example, production limit, benefit, value chain, and cost structure analysis, and global market-impacting transportation and conveyance channels. It additionally incorporates analyzing such significant components as recent market trends and patterns, market demand, product innovations, industrial alliances, mergers and acquisitions, and other global market impacting factors.

A systematically sorted out Market Analysis study Chlorfenapyr depends on the essential and auxiliary approaches. It represents the information accumulated in a more open and clear way reassuring the reader of the report to build up an all-around organized procedure to develop and improve their organizations in normal time.

This market study will discourse the most important issues of the market which are listed below:

Table of Content

Chapter 1 About the Chlorfenapyr Industry1.1 Industry Definition and Types1.2 Main Market Activities1.3 Similar Industries1.4 Industry at a Glance

Chapter 2 World Market Competition Landscape2.1 Chlorfenapyr Markets by Regions2.1.1 USAMarket Revenue (M USD) and Growth Rate 2015-2025Sales and Growth Rate 2015-2025Major Players Revenue (M USD) in 20202.1.2 EuropeMarket Revenue (M USD) and Growth Rate 2015-2025Sales and Growth Rate 2015-2025Major Players Revenue (M USD) in 20202.1.3 ChinaMarket Revenue (M USD) and Growth Rate 2015-2025Sales and Growth Rate 2015-2025Major Players Revenue (M USD) in 20202.1.4 IndiaMarket Revenue (M USD) and Growth Rate 2015-2025Sales and Growth Rate 2015-2025Major Players Revenue (M USD) in 20202.1.5 JapanMarket Revenue (M USD) and Growth Rate 2015-2025Sales and Growth Rate 2015-2025Major Players Revenue (M USD) in 20202.1.6 South East AsiaMarket Revenue (M USD) and Growth Rate 2015-2025Sales and Growth Rate 2015-2025Major Players Revenue (M USD) in 20202.2 World Chlorfenapyr Market by Types2.3 World Chlorfenapyr Market by Applications2.4 World Chlorfenapyr Market Analysis2.4.1 World Chlorfenapyr Market Revenue and Growth Rate 2015-20202.4.2 World Chlorfenapyr Market Consumption and Growth rate 2015-20202.4.3 World Chlorfenapyr Market Price Analysis 2015-2020

Chapter 3 World Chlorfenapyr Market share3.1 Major Production Market share by Players3.2 Major Revenue (M USD) Market share by Players3.3 Major Production Market share by Regions in 2020, Through 20253.4 Major Revenue (M USD) Market share By Regions in 2020, Through 2025

Chapter 4 Supply Chain Analysis4.1 Industry Supply chain Analysis4.2 Raw material Market Analysis4.2.1 Raw material Prices Analysis 2015-20204.2.2 Raw material Supply Market Analysis4.2 Manufacturing Equipment Suppliers Analysis4.3 Production Process Analysis4.4 Production Cost Structure Benchmarks4.5 End users Market Analysis

Chapter 5 Company Profiles5.1 BASF5.1.1 Company Details (Foundation Year, Employee Strength and etc)5.1.2 Product Information (Picture, Specifications and Applications)5.1.3 Revenue (M USD), Price and Operating Profits5.2 American Cyanamid5.2.1 Company Details (Foundation Year, Employee Strength and etc)5.2.2 Product Information (Picture, Specifications and Applications)5.2.3 Revenue (M USD), Price and Operating Profits5.3 Dow AgroScience5.3.1 Company Details (Foundation Year, Employee Strength and etc)5.3.2 Product Information (Picture, Specifications and Applications)5.3.3 Revenue (M USD), Price and Operating Profits5.4 Triveni Interchem5.4.1 Company Details (Foundation Year, Employee Strength and etc)5.4.2 Product Information (Picture, Specifications and Applications)5.4.3 Revenue (M USD), Price and Operating Profits5.5 Kenvos5.5.1 Company Details (Foundation Year, Employee Strength and etc)5.5.2 Product Information (Picture, Specifications and Applications)5.5.3 Revenue (M USD), Price and Operating Profits5.6 Nanjing Gaozheng Agrochemical5.6.1 Company Details (Foundation Year, Employee Strength and etc)5.6.2 Product Information (Picture, Specifications and Applications)5.6.3 Revenue (M USD), Price and Operating Profits5.7 Kaifeng Bokai Biochemistry5.7.1 Company Details (Foundation Year, Employee Strength and etc)5.7.2 Product Information (Picture, Specifications and Applications)5.7.3 Revenue (M USD), Price and Operating Profits5.8 Yonglong Chemical5.8.1 Company Details (Foundation Year, Employee Strength and etc)5.8.2 Product Information (Picture, Specifications and Applications)5.8.3 Revenue (M USD), Price and Operating Profits5.9 Hunan Dejia Biochemical Tech5.9.1 Company Details (Foundation Year, Employee Strength and etc)5.9.2 Product Information (Picture, Specifications and Applications)5.9.3 Revenue (M USD), Price and Operating Profits5.10 Eastman Chemical5.10.1 Company Details (Foundation Year, Employee Strength and etc)5.10.2 Product Information (Picture, Specifications and Applications)5.10.3 Revenue (M USD), Price and Operating Profits

Chapter 6 Globalisation & Trade6.1 Business Locations6.2 Supply channels6.3 Marketing strategy6.4 Barriers to Entry

Chapter 7 Distributors and Customers7.1 Major Distributors and contact information by Regions7.2 Major Customers and contact information by Regions

Chapter 8 Import, Export, Consumption and Consumption Value by Major Countries8.1 USA8.2 Germany8.3 China8.4 Japan8.5 India

Chapter 9 World Chlorfenapyr Market Forecast through 20259.1 World Chlorfenapyr Demand by Regions Forecast through 20259.2 World Chlorfenapyr Price(by Regions, Types, Applications)Analysis Forecast through 20259.3 World Chlorfenapyr Revenue (M USD)(by Regions, Types, Applications) Forecast through 20259.4 World Chlorfenapyr Market Analysis9.4.1 World Chlorfenapyr Market Revenue and Growth Rate 2015-20209.4.2 World Chlorfenapyr Market Consumption and Growth rate 2015-20209.4.3 World Chlorfenapyr Market Price Analysis 2015-2020

Chapter 10 Key success factors and Market Overview

Get Detailed [emailprotected] https://www.regalintelligence.com/request-toc/87892

Thank You.

See original here:
Global Chlorfenapyr Market Executive Summary and Analysis by Top Players 2020-2024: BASF, American Cyanamid, Dow AgroScience, Triveni Interchem,...

Biochemistry

SIU researchers receive grant to study COVID-19 genome, track it through population – SIU News

Koushik Sinha, assistant professor of computer science in SIU Carbondales School of Computing, left, and Keith Gagnon, associate professor of chemistry and biochemistry in the College of Agricultural, Life and Physical Sciences, have received a one-year grant from the Walder Foundation aimed at better understanding and tracking the COVID-19 virus as it moves through populations. SIU will receive about $360,000 of the $500,000 grant, which involves sequencing the virus genomes and using analytic tools to track it. (Photo by Yenitza Melgoza)

October 19, 2020

by Tim Crosby

CARBONDALE, Ill. Although COVID-19 is probably 2020s most common term, many wrongly believe it refers to a specific bug that causes myriad symptoms ranging from fairly mild to deadly.

Researchers know the term actually encompasses a constantly evolving and varying virus that changes as it moves through populations over time. Understanding those changes can tell scientists many things, from its origins to the way it spreads to what it might do next, and unlocking those secrets using genetics and tracking technology is the goal of two researchers at Southern Illinois University Carbondale.

SIU leading the way

Keith Gagnon, associate professor of chemistry and biochemistry in SIUs College of Agricultural, Life and Physical Sciences, and Koushik Sinha, assistant professor of computer science in the School of Computing, will work on a one-year, $500,000 project. The work is aimed at improving our understanding of the virus, with SIU receiving about $360,000 of the money.

Their work is a project of the Chicago Coronavirus Assessment Network (Chicago CAN), an initiative supported by the Walder Foundation.

Under the grant, the Illinois Department of Public Health will supply Gagnons lab with COVID-19 samples from patients mostly located in the Chicago area. Gagnons team will then sequence the virus genomes, and perform evolutionary and phylogenetic analyses on the genome sequences.

Combining data with technology

Gagnon said his lab will sequence the genome of SARS-CoV-2 viruses, which cause COVID-19, from positive patient samples. The study will sequence 5,000 virus genomes over the course of the project.

The genomic and analytic tools we will use should help us understand how the virus is moving and changing over time in the Chicago area by identifying variants of the virus, Gagnon said. We expect to identify the original founder outbreaks of the virus, such as geographic location in the world, and predict when different variants were introduced into the Chicago area.

The lab will sequence and analyze the genomes within two weeks of a positive case, Gagnon said. Combing that information with Google mobility data as practiced by Sinha and his team will reveal the demographics to understand how the virus is affecting certain populations, allowing authorities to make rapid decisions about public health policies.

Bringing analytic tools to the fight

Sinhas team will combine the mutation signatures of each virus, as well as where and when the sample was taken, with powerful analytical tools and map-view visualizations, rapidly sharing results with IDPH and other researchers and making them publicly available for viewing and downloading.

Mapping the diversity of mutations that the virus acquires will provide critical insight into better vaccine development, Gagnon said. And our tools can be used to evaluate the success of future vaccines as they are deployed.

Sinha said the goal is to create a one-stop-shop data and analytics infrastructure for storing, integrating, analyzing and visualizing multiple types of epidemiological data. His group will create a custom visualization and data-analytics platform called COVID-19 Data Map (CoVD-Map). The platform will be an offshoot of the platform that he began developing in spring during some of the early, uncertain months of the pandemic.

Leveraging outside agencies

The teams CoVD-Map will be integrated with the Chicago CAN Commons and designed to work with other public-health surveillance systems, such as Illinoiss National Electronic Disease Surveillance System and the National Notifiable Diseases Surveillance System.

It will be unique in its ability to not only integrate diverse data sources through built-in analytics solutions but also enable researchers to plug in their own analytics tools and visualize their results using its visualization framework, Sinha said.

For instance, one analytic tool will be genomic epidemiology predictions of virus movement and change. The platform also will also integrate with other tools to present results in an intuitive, unified and timely manner, Sinha said.

Information enlightens approaches

The results, incorporating additional dimensions of data, will be accessible to government and health officials, researchers and the public, he said. Health care and government officials can use the CoVD-Map to improve situational awareness and formulate responses while researchers can plug in their own prediction models. Individuals might use it to understand how the pandemic is impacting their areas and accordingly change their daily activity patterns.

The advances the teams hope to make might eventually be applied to other theaters and populations.

We hope to expand this study to the broader state of Illinois to look at rural counties, as well, over time, said Gagnon, who also holds and appointment as an associate professor of biochemistry and molecular biology at the SIU School of Medicine.

See the original post here:
SIU researchers receive grant to study COVID-19 genome, track it through population - SIU News

Cell Biology

Retinal Cell Biology Market Research Report, Revenue, Manufactures and Forecast Until 2028 – The Think Curiouser

Future Market Insights (FMI) presents its new, comprehensive study on the Global Retinal Cell Biology Market spanning from 2020 to 2022. Researches at FMI have no left no stone unturned in bestowing readers a comprehensive view of the market, by studying the drivers, trends, challenges, and restraints. Backed by historical data and projected data, the report breaks down the vast study into numerous geographies and end-use segments, among others to condense the research.

Analysts at FMI have employed in-depth analysis to offer a lucid understanding of the market and the factors shaping its growth trajectory. Ranging from macro socio-economic factors to micro geography-specific trends, the research has taken into consideration every facet that is likely to play a vital role in the growth of the market in the years to come. Presenting a plethora of valuable information, the report will serve as an effective tool, guiding the market players in making fruitful decisions in the forthcoming years.

To ease the understanding of the reader, the report uses CAGR to represent the growth of the market and individual segments. According to the study, the global Retinal Cell Biology market is forecasted to grow at a CAGR of ~11.1% during the assessment period.

Sample of Research Report @https://www.futuremarketinsights.com/reports/sample/rep-gb-8663

Impact of COVID-19 on Retinal Cell Biology Market

The unforeseen outbreak of COVID-19, which swiftly metamorphosed into the pandemic of unexpected proportions, has shifted the worlds focus towards the healthcare sector. National governments are closely working with healthcare institutions and pharmaceutical companies to provide effective treatment to patients suffering with the infection. As a result, there has been a reorientation of medical priorities across healthcare institutions with treatment for COVID-19 patients being the utmost priority. This is sure to impact the growth of the Retinal Cell Biology market through the pandemic period.

FMIs report includes a dedicated section expounding both the short-term and long-term impact of the pandemic on the Retinal Cell Biology market. The study is shaped to bolster stakeholders in making the right decisions to mitigate challenges and leverage opportunities through the pandemic.

Why Choose Future Market Insights?

Retinal Cell Biology Market: Segmentation

To simply the gargantuan study, the report is segregated on the basis of different segments.

Based on drug class

Based on indication

By Region:

The aforementioned segments are studied with respect to each individual region, considering the region-specific trends, drivers and restraints.

Request for covid19 Impact Analysis @ https://www.futuremarketinsights.com/checkout/8663

Key Questions Answered in FMIs Retinal Cell Biology Market Report

ABOUT US:

Future Market Insights is the premier provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in London, the global financial capital, and has delivery centers in the U.S. and India.

FMIs research and consulting services help businesses around the globe navigate the challenges in a rapidly evolving marketplace with confidence and clarity. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. We continuously track emerging trends and events in a broad range of end industries to ensure our clients prepare for the evolving needs of their consumers.

CONTACT US:

Mr. Abhishek Budholiya

Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,

Jumeirah Lakes Towers, Dubai,

United Arab Emirates

MARKET ACCESS DMCC Initiative

For Sales Enquiries:[emailprotected]

For Media Enquiries:[emailprotected]

Original post:
Retinal Cell Biology Market Research Report, Revenue, Manufactures and Forecast Until 2028 - The Think Curiouser

Cell Biology

Educational Foundation of Alfred, Inc. welcomes Nixon, Shaloo to board – Hornell Evening Tribune

Staff reports| The Evening Tribune

ALFRED The Educational Foundation of Alfred, Inc., a private foundation representing faculty, staff, and friends of Alfred State College (ASC), recently welcomed Valerie Nixon and Dr. Ashley Shaloo as new board members.

Nixon is an executive vice president emeritus at Alfred State who served the college for more than 30 years before her retirement in 2019. Her roles at ASC included executive vice president, interim college president, vice president for administration and enrollment, vice president for enrollment management, and director of financial aid. Among her honors are the SUNY Chancellors Award for Excellence in Professional Service and the SUNY Financial Aid Professionals William A. Troy Service Award. Before joining Alfred State, she held positions at Alfred University, the Rochester Institute of Technology, and The College at Brockport.

Nixon holds a bachelors degree in business administration from SUNY Fredonia and a Master of Professional Studies degree in community services administration from Alfred University. She resides in Canisteo with her husband, Robert.

Shaloo is an assistant professor in Alfred States Physical and Life Sciences Department. She serves as the program director for the biological science associate degree program, teaches at least 18 credit hours per semester, and is a co-adviser to the Science Society club.

Shaloo holds a doctorate in molecular and cell biology from Uniformed Services University of the Health Sciences and a Bachelor of Science in biology from Georgian Court University. She resides in Alfred Station.

Read the original post:
Educational Foundation of Alfred, Inc. welcomes Nixon, Shaloo to board - Hornell Evening Tribune

Cell Biology

Reaction Biology and 4HF Biotec Announce Bioinformatic Cell Service – BioSpace

FREIBURG, Germany, Oct. 19, 2020 /PRNewswire/ --Reaction Biology Corp., a drug discovery CRO with offices in Pennsylvania and Germany, and 4HF Biotec GmbH, a bioinformatics firm based in Freiburg, Germany, today announced a new cell-based service offering. The new service combines Reaction Biology's ProLiFiler cell assay service with 4HF's Biomarker Analysis and MOA Finder tools. 4HF Biotech has built a comprehensive database including data from more than 1,800 preclinical samples comprising multiple cancer datasets that are integrated into a single platform for visualization and statistical analysis. The data relevant for the Biomarker Analysis Tool are mutations (whole-exome sequencing), gene copy numbers, and gene expression data. The MoA Finder tool aims to identify the mode of action (MoA) of the test compound by comparing the sensitivity profile of the drug candidate to that of known drugs.

Results of Reaction Biology's 140 cell line assay will be put through both tools of Biomarker Analysis and MOA Finder to give customers a comprehensive understanding of their drug candidates. For Biomarker Analysis, a correlation analysis is performed for each cell line to determine the correlation of the drug sensitivity to each gene with regard to the expression level, mutation status, and/or somatic copy number. For MoA Finder, the test compound's sensitivity profile is compared to more than 700 drugs for which the Mode of Action is known.

"This will give our customers deep insight into the likely genetic response to the drug candidates they test with us," said Dr. Haiching Ma, Chief Science Officer of Reaction Biology. "A cell profile study can shine a spotlight on what a compound is doing, but combining that with 4HF's bioinformatics creates a roadmap for our customers' further development."

"Seeing the phenotypic effects of a compound is only half the information required for an informed drug discovery decision," said Dr. Vincent Vuaroqueaux, CSO of 4HF. "Our bioinformatic approach to building an oncological drug response profile will provide the other half. The Reaction Biology platform is the perfect application for our data analytics."

The service will be performed at Reaction Biology's labs, collaborating with 4HF for analysis. Both companies' labs are in Freiburg.

About Reaction Biology: Founded in 2001, the company provides a full suite of preclinical drug discovery services to over 1600 customers worldwide. It maintains lab facilities in Malvern PA and Freiburg Germany, with sales offices in the US, Germany, France, the UK, Japan, and China. http://www.reactionbiology.com

About 4HF Biotec: 4HF Biotec GmbH was founded in June 2015 by Prof. Dr. H.H. Fiebig. The company is specialized in bioinformatics and data analytics for discovery of innovative therapies to treat cancers. Its team includes experts in medical oncology, anticancer drug evaluation, genomics and bioinformatics. http://www.4hfbiotec.com

Contacts:

Dr. Haiching Ma, CSO Reaction Biology Corporation, +1 610 722 0247, 256966@email4pr.comDr. Vincent Vuaroqueaux, CSO 4HF Biotec GmbH, +49 761 708893-10, 256966@email4pr.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/reaction-biology-and-4hf-biotec-announce-bioinformatic-cell-service-301154559.html

SOURCE Reaction Biology Corporation

See the original post here:
Reaction Biology and 4HF Biotec Announce Bioinformatic Cell Service - BioSpace

Cell Biology

Harvard Business School and Harvard’s Department of Stem Cell and Regenerative Biology Receive $25 Million Gift from Chris and Carrie Shumway to…

Harvard Business School (HBS) and Harvards Department of Stem Cell and Regenerative Biology (HSCRB) have received a $25 million gift from Chris and Carrie Shumway (MBA 1993) to fund programs promoting leadership in life sciences, including the MS/MBA Biotechnology: Life Sciences, a joint degree offered by HBS and the Graduate School of Arts and Sciences and Harvard Medical School through HSCRB. The gift will help bridge the worlds of business and science by fostering an environment of collaboration and innovation at HBS and across Harvard, supporting work on pathbreaking research and educating a new generation of leaders in the life sciences. The gift will provide support for curriculum development and programming, faculty research, and student financial aid.

Every day we are contending with the challenges posed by a worldwide pandemic and seeing firsthand the importance of strong connections between the lab bench and the private sector, said Harvard President Larry Bacow. The Shumways have given us the opportunity to think deeply about how we train leaders at this intersection that will only grow in complexity and importance. We are grateful for their foresight and their exceptional generosity.

This gift will provide the University with the resources to support future leaders in life sciences, dramatically increase innovation and the commercialization of new discoveries, and efficiently and quickly take transformative discoveries from the laboratory to patients and the marketplace, said HBS Dean Nitin Nohria. The world needs more business leaders working at the intersection of science and society, with deep understanding of not only biotechnology and life sciences, but the management skills needed to help these important companies thrive.

To meet this need, the MS/MBA Biotechnology: Life Sciences Program, welcomed its first cohort of students this past August. In supporting financial aid that will cover the incremental costs of the MS/MBA program for these students, this gift will enable Harvard to attract and support outstanding students who already have experience and knowledge in life sciences. To recognize this support, the students in this program will be known as Shumway Fellows and this program will prepare them to take on leadership roles in biotechnology and life sciences organizations.

The program builds upon students existing biotech and life sciences knowledge and equips them with the latest business and scientific insights. This empowers them to launch, grow, and lead transformative organizations that will advance new drug discoveries or therapeutics. Students in the program study general management at HBS and life-sciences at HSCRB, which is a joint department of Harvards Faculty of Arts and Sciences (FAS) and Harvard Medical School (HMS). They benefit from the leadership of program co-chairs Amitabh Chandra (Henry and Allison McCance Professor of Business Administration at HBS and the Ethel Zimmerman Winer Professor of Public Policy and Director of Health Policy Research at the Harvard Kennedy School of Government) Mark Fishman (Professor of Stem Cell and Regenerative Biology at Harvard University and Chief of Pathways Consult Service at Massachusetts General Hospital), and Douglas Melton (Xander University Professor at Harvard University and Co-Director of the Harvard Stem Cell Institute).

The MS/MBA program is a collaborative effort from several schools across Harvard to fill a unique need we see in the industry, said Emma Dench, dean of GSAS. The program provides students with the opportunity to become conversant in both biomedical science and business, and this generous gift will help to ensure that we can prepare them to lead in the rapidly growing life sciences fields.

The future of life sciences innovation will increasingly require deep scientific knowledge coupled with targeted business acumen, said George Q. Daley, dean of HMS. With this joint degree, Harvard will be uniquely positioned to educate students to lead at this nexus.

Sometimes it is at the intersection of disciplines where we find opportunities to ask new questions that have the potential to completely change the way we think about a problem, said Edgerley Family Dean of the Faculty of Arts and Sciences Claudine Gay. This gift will enable Harvard to attract and support talented scholars in the life sciences and equip them with the tools they need to work at the interface of business and life sciences, asking the new questions that promote discovery and innovation in this important area.

Harvard has created an exceptional ecosystem that can develop and cultivate talented professionals across medicine, business and life sciences who are best positioned to tackle the worlds biggest global health challenges today and in the future, said Chris Shumway, managing partner and founder of Shumway Capital. As Harvard is geographically situated at the epicenter of the life sciences community with access to some of the worlds leading hospitals, pharma and biotechnology companies, we believe a tremendous opportunity exists to foster cross-pollination of ideas by marshalling the resources of Harvard and connecting with industry leaders to quickly understand and solve problems.

The gift will also support HBS as it engages and works closely with entrepreneurs and practitioners in the field on the creation of new research and the development of executive education training to serve their unique needs.

The acceleration of global health issues, including the current pandemic, demonstrates the need for entrepreneurial thinking, Chris Shumway added. Leaders born out of these programs will be equipped to drive organizations at the forefront of groundbreaking discoveries with the mindset needed to solve complex problems worldwide.

As an entrepreneur and Managing Partner of Shumway Capital, Chris Shumway has invested in, advised, and built growth businesses for over 25 years, including in biotechnology and life sciences. The Shumways are long-time supporters and advocates for philanthropic initiatives. As strong proponents of education reform, they established the Shumway Foundation with the primary goal of helping to break the cycle of poverty through better opportunities in education. The Shumway Foundation also actively supports other results-based non-profit organizations.

Read this article:
Harvard Business School and Harvard's Department of Stem Cell and Regenerative Biology Receive $25 Million Gift from Chris and Carrie Shumway to...

Cell Biology

Phosplatin Therapeutics Announces Presentation of Research into PT-112 Mechanism of Action at the 32nd EORTC-NCI-AACR Virtual Symposium – BioSpace

NEW YORK, Oct. 20, 2020 /PRNewswire/ -- Phosplatin Therapeutics LLC, a clinical stage pharmaceutical company focused on oncology therapeutics, today announced that data revealing novel mechanistic attributes of its lead candidate PT-112, an immunogenic cell death (ICD) inducer under Phase 2 development, will be presented at the 32nd Symposium of the European Organisation for Research and Treatment of Cancer (EORTC), the National Cancer Institute (NCI) and the American Association for Cancer Research (AACR) taking place virtually from October 24-25.

Title:

PT-112, A First-In-Class Pyrophosphate-Platinum Conjugate, Selectively Targets Highly Glycolytic Tumor Cells (catalog number 188)

Abstract availability:

Saturday, October 24, 2020 on EORTC-NCI-AACR symposium site and on the Phosplatin Therapeutics web site

Session:

New Drugs Poster Session (code 380)

Lead Author:

A. Anel, University of Zaragoza /Aragn Health Research Institute, Biochemistry and Molecular and Cell Biology, Zaragoza, Spain

Building upon prior publication of the ICD effects of PT-112, the body of work to be presented is part of an effort to understand the metabolic pathways and cellular targets affected by PT-112 upstream of ICD initiation. "The data to be reported at the 32nd EORTC-NCI-AACR Virtual Symposium advance the body of knowledge around PT-112's pleiotropic mechanism of action and provide valuable information on further potential clinical applications of PT-112. As we continue our clinical study of this unique compound in patients with challenging cancers, such insights are important," said Robert Fallon, co-founder and chief executive officer, Phosplatin Therapeutics. "We are pleased to co-present this body of work under our fruitful collaboration with the Anel lab at the University of Zaragoza, Spain."

About PT-112

PT-112 is a novel small molecule conjugate of pyrophosphate that possesses a unique pleiotropic mechanism of action that promotes immunogenic cell death (ICD), through the release of damage associated molecular patterns (DAMPs) that bind to dendritic cells and lead to downstream immune effector cell recruitment in the tumor microenvironment. PT-112 represents the best-in-class small molecule inducer of this immunological form of cancer cell death and is currently under Phase II development. The rst in-human study of PT-112 demonstrated an attractive safety prole and evidence of long-lasting responses among heavily pre-treated patients and won "Best Poster" within the Developmental Therapeutics category at the ESMO 2018 Annual Congress. The novelty of PT-112's pyrophosphate moiety also results in osteotropism, or the propensity of the drug to reach the mineralized bone. This property is of interest in cancer types that originate in or metastasize to the bone. The combination Phase Ib study of PT-112 with PD-L1 checkpoint inhibitor avelumab in solid tumors was reported in an oral presentation at the ESMO 2020 Virtual Congress.

About Phosplatin Therapeutics

Phosplatin Therapeutics is a privately held, clinical stage pharmaceutical company that holds exclusive global license to phosphaplatins, a family of small molecules rationally designed to circumvent the mechanisms of drug resistance and toxicity commonly associated with chemotherapeutic regimens. The company's lead candidate, PT-112, is a novel chemical entity under clinical development that exhibits a unique combination of properties, including immunogenic cell death and osteotropism. Clinical data generated to date across three Phase I studies have demonstrated single-agent anti-cancer activity and an attractive tolerability prole, and two Phase II studies of PT-112 are underway. The company's research and development work to date has spanned fteen countries and been funded by private investors and family investment ofces in the United States, Europe and Asia, along with a sub-license agreement for the development, commercialization and use of PT-112 in Greater China. The company sponsors the ongoing clinical study of PT-112 in combination with the PD-L1 inhibitor avelumab under a collaboration agreement with Pzer and Merck KGaA, Darmstadt, Germany (operating as EMD Serono in the US and Canada).

CONTACTS:

Phosplatin TherapeuticsTaylor YoungSenior Director of Strategic DevelopmentTel: +1 646 380 2441Email: tyoung@phosplatin.com

Westwicke, an ICR CompanyInvestors:Stephanie CarringtonTel: +1 646 277 1282Email: Stephanie.Carrington@westwicke.com

Media:Mark CorbaeTel: +1 203 682 8288Email: mark.corbae@westwicke.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/phosplatin-therapeutics-announces-presentation-of-research-into-pt-112-mechanism-of-action-at-the-32nd-eortc-nci-aacr-virtual-symposium-301155292.html

SOURCE Phosplatin Therapeutics

Excerpt from:
Phosplatin Therapeutics Announces Presentation of Research into PT-112 Mechanism of Action at the 32nd EORTC-NCI-AACR Virtual Symposium - BioSpace

Cell Biology

Anti-age your immune system here’s how to turn back the clock – The Times

As with nearly everything else to do with our bodies, the effectiveness of the immune system declines with age. From our twenties onwards the bodys ability to fight infection decreases at a rate of about 2 to 3 per cent a year, gradually leaving us more susceptible to diseases, says Janet Lord, a professor of immune cell biology and the director of the Institute for Inflammation and Ageing at Birmingham University. But, she says, the speed at which this happens is not unavoidable. Ill health should not be an inevitable part of growing old. By understanding what happens to our immune systems as we age, we can break that link.

Ageing of the immune system is accelerated by the usual baddies, smoking, a sedentary lifestyle,

Read the original here:
Anti-age your immune system here's how to turn back the clock - The Times

Cell Biology

Notch Therapeutics Strengthens Leadership Team with Appointment of Kamran Alam as CFO and Gregory Block as SVP, Corporate Development – PRNewswire

TORONTO, Oct. 19, 2020 /PRNewswire/ --Notch Therapeutics Inc., a cell therapy company with a proprietary platform for generating renewable stem cell-derived T cell therapies for cancer and other immune disorders, announced today the appointment of Kamran Alam as Executive Vice President, Finance and Chief Financial Officer and Gregory Block as Senior Vice President, Corporate Development, effective immediately.

"Adding these experienced leaders to our team underpins our strategy of advancing our pipeline and supporting our partnering initiatives," said David Main, President and Chief Executive Officer of Notch. "Their combined expertise in financial and corporate strategy will augment our deep technical team as we advance our proprietary platform that enables the development of highly consistent T cell therapies manufactured at industrial scale and lower cost. We look forward to their contributions as members of our executive team."

Kamran Alam, Executive Vice President, Finance and Chief Financial OfficerKamran Alam brings to Notch more than 20 years of global corporate finance and business development leadership experience. He joins Notch from Neoleukin Therapeutics, where he served as Interim Chief Financial Officer following Neoleukin's merger in 2018 with Aquinox Pharmaceuticals. Previously, in his role as Chief Financial Officer and Vice President, Finance at Aquinox, Mr. Alam provided finance leadership for the company's IPO on the NASDAQ stock exchange in 2014. Prior to his tenure with Aquinox, Mr. Alam held senior roles in business development for a number of biotechnology and pharmaceutical companies. Mr. Alam is a Chartered Professional Accountant. He holds a B.Sc. in Cell Biology and Genetics from the University of British Columbia and an M.B.A. in International Business and Strategy from the University of Victoria.

Gregory Block, Ph.D., Senior Vice President, Corporate DevelopmentGregory Block is a seasoned biotechnology executive with more than 10 years of experience in the development and commercialization of novel therapeutic modalities. Prior to his position with Notch, he served as Director of Business Development for Astellas Pharmaceuticals, where he led business development and strategic initiatives for regenerative medicine and cell therapy immune oncology. Dr. Block joined Astellas via the company's 2018 acquisition of Universal Cells Inc., where he was instrumental in company-building and business development. Dr. Block holds a Ph.D. in Molecular Biology from Tulane University and completed a fellowship at the University of Washington.

About Notch Therapeutics (www.notchtx.com)Notch Therapeutics is a cell therapy company that has unlocked the ability to produce T cells and other cells from any source of stem cells. At the core of the Notch technology is the Engineered Thymic Niche (ETN) platform, which enables precision control of cell fate during the differentiation and expansion of stem cells. The ETN is the first technology that can reliably generate T-cells from iPSC-derived progenitor cells using fully defined, non-xenogenic reagents at industrial scale. By leveraging the ETN platform, Notch is positioned to design and deliver the next generation of T cell therapeutics that are specifically engineered to address the underlying biology of complex disease systems. The technology was invented in the laboratories of Juan-Carlos Ziga-Pflcker, Ph.D. at Sunnybrook Research Institute and Peter Zandstra, Ph.D., FRSC at the University of Toronto. Notch was founded by these two institutions, in conjunction with MaRS Innovation (now Toronto Innovation Acceleration Partners) and the Centre for Commercialization of Regenerative Medicine (CCRM) in Toronto.

Contact:Mary MoynihanM2Friend Biocommunications802-951-9600[emailprotected]

SOURCE Notch Therapeutics

Follow this link:
Notch Therapeutics Strengthens Leadership Team with Appointment of Kamran Alam as CFO and Gregory Block as SVP, Corporate Development - PRNewswire